<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82560">
  <stage>Registered</stage>
  <submitdate>27/05/2008</submitdate>
  <approvaldate>24/09/2008</approvaldate>
  <actrnumber>ACTRN12608000476336</actrnumber>
  <trial_identification>
    <studytitle>International Study to Predict Optimized Treatment - in Depression</studytitle>
    <scientifictitle>International Study to Predict Optimized Treatment response to the three most commonly used antidepressants  (Escitalopram, Sertraline and Venlafaxine extended release XR,) in subjects diagnosed with major depressive disorder (MDD) as compared to matched healthy controls.</scientifictitle>
    <utrn />
    <trialacronym>iSPOT-D</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Major Depressive Disorder (MDD)</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Once randomised and on drug, subjects will be dosed with study medication as per local/country standard of care. Therefore,  the length of treatment will differ and is based on the subjects response.

escitalopram one 10 mg tablet orally once daily (QD)
sertraline one 50 mg orally QD
venlafaxine extended release (XR) one 75 mg orally QD</interventions>
    <comparator>matched healthy subjects not taking medication</comparator>
    <control>Historical</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite markers from 165 different assessments/variables will be assessed to identify genetic, brain structure/function and cognitive markers (or combination of markers) which predict acute drug treatment response in MDD. This will be assessed using:

The MINI International Neuropsychatric Interview.
Hamilton Rating of Depression Scale (HAM-D21).
Web based questionnaire (web-Q), including:
Depression, Anxiety and Stress Scale (DASS42).
Neuroticism, Extraversion, and Openness Five Factor Inventory (NEO-FFI).
Emotion Regulation Questionnaire (ERQ).
Satisfaction with Life Scale (SWLS).
Quick Inventory of Depressive Symptomatology (QIDS-SR)
CORE Rating Scale 
Columbia Atypical Depression Diagnostic Scale (ADDS)
Visual Analogue Scale for both physical and psychological pain
Clinical Global Impression (CGI)
26-item World Health Organisation Quality of Life Scale Brief Version (The WHOQOL)
Social and Occupational Functioning Assessment Scale (SOFAS)
Self Rated Global measure of the Frequency, Intensity and Burden of Side Effects Rating (FIBSER).

Psychophysiological assessment (including, respiratory rate, sweat rate, EEG and Event Related Potential) and a Cognitive test battery. 
Symptom and sub-type assessment.
Full Genetic array analysis.
Structural and functional MRI.</outcome>
      <timepoint>Week 8</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine whether markers of acute treatment prediction are also predictive of functional outcome over 6-12 months. Using Quick Inventory of Depressive Symptomatology (QIDS) and the Self Rated Global measure of the Frequency, Intensity and Burden of Side Effects Rating (FIBSER).</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)criteria for primary Major Depressive Disorder with a Hamilton Rating Depression Scale (HAM-D) score &gt;/= 16 and who are fluent in English or Dutch.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Presence of suicidal ideations, biopoloar, psychosis or primary eating disorder.
Prior or resent use antidepressants including escitalopram, sertraline, venlafaxine XR.
History of brain injury/blow resulting in loss of consciousness.
evere impediment to vision, hearing and/or hand movement which may interfere with their ability to complete the protocol required test.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Study staff to contact an interactive web randomisation system.</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/07/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>2688</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate />
    <postcode>2145</postcode>
    <postcode>3122</postcode>
    <postcode>5042</postcode>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Brain Resource</primarysponsorname>
    <primarysponsoraddress>Level 12, 235 Jones Street
Ultimo, NSW 2007</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Brain Resource</fundingname>
      <fundingaddress>Level 12, 235 Jones Street
Ultimo, NSW 2007</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Copernicus Group IRB</ethicname>
      <ethicaddress>Copernicus Group IRB
One Triangle Drive, Suite 100,
P.O. Box 110605
Research Triangle Park, NC  27709</ethicaddress>
      <ethicapprovaldate>7/05/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>SWAHS</ethicname>
      <ethicaddress>Human Research Ethics Committee
Westmead Campus
Research Office, RM 2020 Clinical Sciences
Hawkesbury Rd
Westmeas, NSW 2145</ethicaddress>
      <ethicapprovaldate>14/07/2008</ethicapprovaldate>
      <hrec>HREC2008/4/4.17 (2726)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Patrick Hopkinson</name>
      <address>Level 12, 235 Jones Street
Ultimo, NSW 2007</address>
      <phone>+61 (0)2 9211 7120</phone>
      <fax />
      <email>patrick.hopkinson@brainresource.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mimma Mason</name>
      <address>Level 12, 235 Jones Street
Ultimo, NSW 2007</address>
      <phone>+61 (0)2 9211 7120</phone>
      <fax />
      <email>mimma.mason@brainresource.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Deborah Kargl</name>
      <address>Level 12, 235 Jones Street
Ultimo, NSW 2007</address>
      <phone>+61 (0)2 9211 7120</phone>
      <fax />
      <email>deborah.kargl@brainresource.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>